By Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more
NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more
By Beth Fand Incollingo
The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more
By Dr. Peter Argenta
COVID-19 has really made a mess of healthcare across the board—not just in America, but for the entire world, says Dr. Peter Argenta, a gynecologic oncologist at the University of Minnesota Health Cancer Care. And … Read more
By Hannah Slater
The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1
Efficacy for … Read more
by Marilynn Marchione
For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease.
The test is still experimental. … Read more
By Jo Cavallo
The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more
BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its
By Peter Hofland, Ph.D
Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.[1]
The trial was designed to study … Read more
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development … Read more
By Shim Hyun-tai
Antibody-based therapeutics developer Abclon said Tuesday that it has successfully drawn final candidates for the clinical trials of the next-generation chimeric antigen receptor T (CAR-T) cell therapy for ovarian cancer.
Abclon plans to enter clinical trials in … Read more
By Pam Harrison
Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.
In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more
Toronto, Canada—Findings from a phase 2 study prepared for presentation at the 2020 SGO Annual Meeting on Women’s Cancer showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.
“Angiogenesis inhibition is a valuable strategy for … Read more
By Lisa Astor
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival … Read more
Scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.
Led by Professor John Hooper, the TRI-based Mater … Read more
By Brita Belli
A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more
By Gina Columbus
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II … Read more
By Gina Columbus
The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more
By Leah Lawrence
History of sexually transmitted infections (STIs) may be important in the etiology of ovarian cancer — and a new study links certain STIs with increased risk for the disease.
Using data from the European Prospective Investigation into … Read more
By Denise Myshko
Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more
